Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 6,463 $ 7,279
Marketable securities, current 56,571 58,390
Collaboration receivable 4,263 18,094
Prepaid expenses and other current assets 2,845 2,246
Total current assets 70,142 86,009
Marketable securities, non-current 12,181 16,364
Property and equipment, net 690 686
Other assets 1,159 1,059
Total assets 84,172 104,118
Current liabilities:    
Accounts payable 2,891 1,689
Accrued clinical and development expenses 7,173 7,444
Accrued liabilities 2,511 3,161
Deferred revenue, current 14,722 14,722
Total current liabilities 27,297 27,016
Warrant liability 15,299 23,421
Deferred revenue, non-current 69,555 76,916
Deferred rent 274 240
Total liabilities 112,425 127,593
Commitments and contingencies (Note 7)      
Stockholders’ equity (deficit):    
Preferred stock, $0.001 par value, 2,000,000 shares authorized; no shares issued and outstanding      
Common stock, $0.001 par value, shares authorized: 150,000,000 shares; issued and outstanding: 59,365,233 shares at June 30, 2014 and 59,232,611 shares at December 31, 2013 59 59
Additional paid-in capital 331,224 328,116
Accumulated other comprehensive gain (loss) 17 28
Accumulated deficit (359,553) (351,678)
Total stockholders’ equity (deficit) (28,253) (23,475)
Total liabilities and stockholders’ equity (deficit) $ 84,172 $ 104,118